Study met primary and all key secondary efficacy endpoints
Participants receiving DT120 ODT achieved a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) score, with a placebo-adjusted change of 5.4 points from baseline at Week 12 (p<0.0001, Cohen’s d=0.81)
DT120 ODT was generally well tolerated, with a safety profile consistent with prior clinical experience
Company to host webcast today at 8:00 am EDT
Gene expression patterns could help explain why some patients don’t respond well to anti-rejection therapiesContinue reading
Across Arizona, auditorium lights dim, applause swells, and hundreds of aspiring healthcare professionals step forward to mark their entry into patient care. Whether donning crisp white coats or receiving stethoscopes, these ceremonies represent one of medicine’s most poignant rites of passage—a dynamic transition from textbook study to clinical practice. In 2026, these milestones across the Grand Canyon State carry heightened significance, serving as both a personal achievement for students and a vital sign of hope for Arizona’s expanding medical and life sciences infrastructureContinue reading
Arizona State University researchers have received a new $465,000 grant from the National Institutes of Health to expand on their research of how micro- and nanoplastics may accumulate in the aging human brain, and whether their presence is associated with Alzheimer’s diseaseContinue reading
The funding accelerates deployment of the first agentic medical assistant that autonomously calls patients before visits, captures structured clinical histories, and writes intake notes directly into the EHR, thereby reshaping how health systems approach the front door of care.
Phoenix, Arizona, August 3, 2026: BioLab Holdings, Inc. has announced the publication of a peer-reviewed real-world evidence (RWE) study demonstrating promising clinical outcomes for its Membrane Wrap™ human amniotic tissue membrane in the treatment of complex pressure ulcers. Published in the International Journal of Tissue Repair, the multicenter pilot feasibility study evaluated Membrane Wrap™ in combination with standard of care (SOC) compared with standard wound care alone, highlighting the potential of placental-based regenerative therapies to improve healing outcomes in patients with chronic wounds. The study analyzed de-identified electronic health record data from the U.S. Wound Registry and Intellicure database, involving 182 patients across multiple healthcare settings. Results showed that 63.7% of patients treated with Membrane Wrap™ plus standard care were classified as healing or healed, compared with 48.4% of patients receiving standard care alone. The findings further strengthen BioLab’s growing body of clinical evidence supporting advanced wound care technologies designed to enhance tissue restoration and improve patient outcomes.Continue reading
Scottsdale, AZ and Boca Raton, FL — August 4, 2026 — CND Life Sciences, a leading neurodiagnostics company advancing objective biomarker-based testing for neurodegenerative diseases, today announced the completion of growth financing led by S-Curve Partners, an operator-led healthcare investment firm focused on founder-inspired healthcare technology and diagnostics businesses. S-Curve was joined by current CND investors and shareholders, reflecting continued confidence in the Company’s commercial trajectory, expanding clinical adoption, and long-term strategic positioningContinue reading
Share exchange establishes NanoRx as the drug delivery platform technology provider and EnduRx as the developer of use-casesContinue reading
A new study highlights how a decade of investment in research commercialization is translating discoveries into high-impact companies.
Continue reading
Business & Bioindustry: Arizona’s collaborative ecosystem drives discovery and growth is the cover story of the August 2026 issue of In Business Magazine – Greater Phoenix.Continue reading